| |
|
|
|
|
| March 11,
2010 | ISSUE NUMBER 139 VOL 8 |
Clinical Trials
Two Drugs Fail in Trials
Monday was a gloomy day for industry as two separate drug trials went belly up. AstraZeca’s Recentin proved that it wasn’t up-to-snuff compared with Avastin, and the Roche/Biogen Idec arthritis collaboration treatment, ocrelizumab, may have led to fatalities.
Marketing
PhRMA Calls for New Style Search Link Ads
The pharma industry’s lobby group is pitching its plan for a new style of search engine ads. Is PhRMA stepping on Google’s territory, or is the group just trying to make it easier for industry to Tweet?
Branding
Kapidex Gets a New Name
Citing confusion with two other similarly named drugs, Takeda decided to give its proton pump inhibiter a new moniker: Dexilant.
|
Call for Nominations
Pharmaceutical Executive¹s Emerging Pharma Leadership Award
The pharma industry is facing some tough times‹and the old way of doing things just won¹t work. So just who are the new leaders steering the industry though its most difficult challenges? Which executives are revamping the industry‹through pure innovation‹to remake it for the 21st century?
These emerging leaders are vital to the future of the industry, and you can help ensure that they get the recognition they deserve. Fill out your nomination today! |
 |
|  Vermillion appointed Carl Severinghaus to its board.
// China Yongxin Pharmaceutical added Hal Lieberman, Laura Philips, Bing Li, and Jingang Wang to its board as independent directors.
// Afraxis appointed David Campbell chief scientific officer and Carmine Stengone as VP of corporate development.
// 3SBio added Peiguo Cong to its board as an independent, non-executive editor.
// Song Jinan, Chin Ji Wei, Simon Yick and Du Wen Min were elected directors of China-Biotics.
// Vermillion announced its scientific advisory board: Robert Bast Jr., Walter Carney, Daniel Chan, John Cooke, and Gordon Whiteley.
// Cylex elected Richard Sandberg to its board.
//
|
The BIO International Convention Returns to Chicago!
Mark your calendars for the global event for biotechnology, May 3-6, 2010, at Chicago’s McCormick Place. Join more than 15,000 executives, investors, scientists, researchers, policy makers and journalists from around the world for strategic discussions, BIO Business Solutions® and new opportunities in biotech. Access the expert knowledge and resources you need to Heal, Fuel, Feed The World®. Visit
 convention.bio.org
|
|
|
|
 |
|
 |
|
 |
| Will open-source research and development have a positive effect on the industry? |
|
|
|
|
You
are subscribed to %%list.name%% as %%emailaddr%%. To unsubscribe
from this list click
here.To
ensure delivery to your Inbox, please add %%email.list%% to your
address book. If you need help doing this, click
here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
